• Estradiol Receptor–Autophagy Axis Protects Organs in Perimen

  2026-06-22

  This study elucidates how declining 17 beta-estradiol levels during perimenopause increase metabolic, cardiovascular, and renal disease risk by disrupting estrogen receptor–dependent autophagy. Integrating human cohort data, network pharmacology, and mouse models, the research defines receptor- and autophagy-specific mechanisms underlying estradiol's multi-organ protective effects, informing precision hormone therapy strategies.

• Chlorpromazine Hydrochloride in Antipsychotic and Hepatic Re

  2026-06-22

  Explore how chlorpromazine hydrochloride powers advanced antipsychotic and liver nanoparticle interaction studies, bridging neuropharmacology with nanomedicine workflows. This guide details practical protocols, troubleshooting, and unique insights from recent cellular uptake research.

• Estradiol (A8425): Mechanistic Insights and Research Utility

  2026-06-21

  Estradiol (17 beta-estradiol) is a potent estrogen receptor modulator essential for reproductive, cardiovascular, and metabolic research. Recent evidence shows its organ-protective effects are mediated by ERα/ERβ and autophagy pathways, with precise molecular benchmarks. APExBIO’s A8425 product enables reproducible assays for these mechanisms.

• Radiopathomics Signature Predicts Immunotherapy Response in

  2026-06-20

  This study presents a multimodal radiopathomics signature (RPS) that integrates imaging and pathology data using interpretable machine learning to predict immunotherapy response in gastric cancer. The RPS outperformed conventional biomarkers and revealed associations with immune regulation, providing a new avenue for personalized treatment stratification.

• S Tag Peptide (A6007): Technical Guidance for Protein Taggin

  2026-06-19

  S Tag Peptide addresses key challenges in recombinant protein detection, purification, and solubility enhancement by serving as a reliable N- or C-terminal fusion tag. It is best suited for workflows that require anti-S-Tag antibody detection and affinity purification but should not be selected where ethanol solubility or long-term aqueous storage is needed.

• NF 449: Advanced Insights into P2X1 Antagonism and Assay Des

  2026-06-19

  Explore the unique mechanism and advanced experimental value of NF 449, a highly selective purinergic receptor antagonist for P2X1. This article delivers a deeper analysis of assay design, selectivity, and translational considerations beyond standard platelet aggregation studies.

• Lypressin Acetate: Advanced Workflows for Vasopressor & Anti

  2026-06-18

  Lypressin acetate stands apart as a potent, well-characterized vasopressin analog with proven antidiuretic, vasoconstrictive, and emerging antiviral capabilities. This guide delivers actionable protocols, troubleshooting insights, and comparative advantages to empower researchers leveraging APExBIO’s Lypressin acetate for both classic and translational domains.

• Arachidonic Acid in Neurovascular Research: Beyond Inflammat

  2026-06-18

  Explore the pivotal role of arachidonic acid, a polyunsaturated omega-6 fatty acid, in neurovascular research. This article delves into its molecular mechanisms, translational applications, and advanced assay design, setting a new benchmark beyond standard inflammation workflows.

• Thrombin B Chain: Translational Leverage in Coagulation and

  2026-06-17

  This article explores the mechanistic and translational significance of the Coagulation Factor II (Thrombin) B Chain Fragment, SKU A1057, emphasizing its unique value for experimental design, disease modeling, and strategic innovation in vascular and hemostatic research. Drawing on evidence from peer-reviewed studies and advanced product features, it delivers actionable guidance for researchers navigating the evolving landscape of coagulation biology and therapeutic development.

• L-Phenylephrine: Applied Use for Adrenergic α1A Receptor Res

  2026-06-17

  L-Phenylephrine, a selective adrenergic α1A receptor agonist, is pivotal for dissecting cardiovascular and neural signaling pathways. This guide delivers actionable workflows, troubleshooting insights, and evidence-driven protocol enhancements for researchers modeling vasoconstriction, hypertrophy, and sex-specific responses.

• Angiotensin II in Vascular Remodeling: Protocols & Pitfalls

  2026-06-16

  Leverage Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) as a gold-standard tool for dissecting hypertension mechanisms and modeling complex vascular pathologies. This guide details optimized workflows, troubleshooting insights, and how recent neurovascular innovations reshape experimental choices.

• Tri-Color Precision: Advancing Translational SDS-PAGE Standa

  2026-06-16

  Explore how APExBIO’s Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) empowers translational researchers to bridge mechanistic cell death insights—such as UV-induced ribotoxic stress response—with rigorously validated, phosphoprotein-compatible workflows. This article unpacks the mechanistic rationale for precision protein sizing, cross-validates with recent breakthroughs, and provides actionable protocol guidance for maximizing reproducibility in SDS-PAGE and Western blotting.

• Tankyrase Inhibition Suppresses Liver Cancer via Hippo Pathw

  2026-06-15

  Jia et al. (2017) demonstrate that selective tankyrase 1/2 inhibitors, including G007-LK, suppress hepatocellular carcinoma cell growth by modulating the Hippo-YAP signaling cascade. The study uncovers a mechanism involving stabilization of AMOTL1/2 proteins and downregulation of YAP activity, providing a foundation for future research into targeted therapies for liver and other Wnt/β-catenin-driven cancers.

• Bafilomycin C1: Precision V-ATPase Inhibitor for Autophagy A

  2026-06-15

  Bafilomycin C1 stands out as a gold-standard vacuolar H+-ATPases inhibitor, enabling robust interrogation of autophagy, lysosomal acidification, and high-content phenotypic screening, especially in iPSC-derived models. Its specificity and reliability make it indispensable for workflows from early drug safety de-risking to mechanistic disease studies.

• HDAC Inhibitors as NUT Function Repressors in NUT Carcinoma

  2026-06-14

  Shiota et al. present a high-throughput chemical screen revealing diverse histone deacetylase (HDAC) inhibitors as potent repressors of NUT-driven transcription in NUT carcinoma. This work elucidates both mechanistic underpinnings and translational relevance for targeting chromatin regulation in aggressive squamous cancers.

494 records 10/33 page Previous Next First page 上5页 678910 下5页 Last page